Although GSK3β has been reported to have contrasting effects on the progression of different tumors, it's possible functions in esophageal squamous cell carcinoma (ESCC) and the related molecular mechanisms remain unknown. Here, we investigated the expression, function, and molecular mechanism of GSK3β in the development of ESCC in vitro and in vivo. Though the expression of total GSK3β was significantly increased, the phosphorylated (inactivated) form of GSK3β (Ser9) was concurrently decreased in the cancerous tissues of patients with ESCC compared with controls, suggesting that GSK3β activity was enhanced in cancerous tissues. Further pathological data analysis revealed that higher GSK3β expression was associated with poorer differentiation, higher metastasis rates, and worse prognosis of ESCC. These results were confirmed in different ESCC cell lines using a pharmacological inhibitor and specific siRNA to block GSK3β.
still very high, and the prognosis remains unsatisfactory. 4, 5 The annual incidence rate of esophageal cancer is 3/10 5 person-years in the US white population [6] [7] [8] and reaches 1000/10 5 person-years in some areas of China. 8, 9 The median survival time of patients with inoperable cancer is estimated to be only 13-29 months, and the 5-year survival rate of EC patients is only 10-20% after radiotherapy or esophagotomy. 4, 8, 10 These epidemiologic results reflect the low efficiency of current treatments, underscoring the need for a deeper understanding of the molecular mechanisms underlying this disease as well as for new therapeutic strategies for its treatment.
As the key protein kinase-mediated signaling events in cancer development have been identified and characterized, strategies aimed at manipulating the activity of protein kinases have been investigated for use in the treatment of a wide range of cancers. Noteworthy examples include the treatment of breast cancer with lapatinib (TYKEB, EGFR/Her-2 inhibitor), 11 kidney cancer with temsirolimus (TORISEL, mTOR inhibitor), 12 T-cell lymphoma with vorinostat (Zolinza, histone deacetylase inhibitor), 13 and skin cancer with vismodegib (Erivedge, Hedgehog blocker). 14 Moreover, more than
30 agents are currently being tested in clinical trials, suggesting a promising future for the application of kinase inhibitors. 15 Therefore, further exploration into the molecular events involved in the development of ESCC may facilitate the identification of diagnostic markers, therapeutic targets, or prognostic indicators for this disease.
Glycogen synthase kinase 3 is a serine/threonine kinase downstream of the PI3K pathway. Two major isoforms, GSK3α and GSK3β, have been identified, and both are widely expressed in most mammalian cells. 16, 17 A distinct feature of GSK3β is its high activity under basal conditions. Phosphorylation at Serine 9 of GSK3β leads to a structural change and decreases its activity. 16 PI3K activation results in Akt phosphorylation and the subsequent phosphorylation/inactivation of GSK3β, which has been demonstrated to suppress the production of pro-inflammatory cytokines including IL-12, TNFα, IL-1β, IL-6, IFNγ, and IL-17, while it concurrently promotes the production of IL-10, IL-1Ra, and IFNβ by immune cells. 10, 18 Moreover, GSK3β is also involved in Wnt signaling pathways. GSK3β inhibition leads to the accumulation of β-catenin in the nucleus, which enhances the progression of most cancers. 19, 20 Since some inflammatory cytokines (e.g., IL-6) and β-catenin are considered to be protumorigenesis factors that induce the initiation and progression of cancer, GSK3β was assumed to play a functional role in cancer biology.
In this regard, opposing roles of GSK3β have been reported in the development of different cancers. [21] [22] [23] Aberrant expression of GSK3β has been shown to promote cell growth in some cancers and to suppress it in others. Several studies have reported the abnormal expression of GSK3β in esophageal cancer cell lines. 24, 25 However, the expression level and activity of GSK3β in the tissue of esophageal patients remains essentially unknown, let alone the molecular mechanism by which GSK3β functions in ESCC.
Signal transducer and activator of transcription-3, also known as STAT3, is a transcription factor required for normal cell growth.
STAT3 is quiescent in the cytoplasm. Phosphorylation at Serine 727
and Tyrosine 705 leads to its dimerization and translocation into the nucleus, where it activates the transcription of target genes. 26 STAT3 has been reported to be constitutively activated in various cancer tissues, and increased STAT3 activation is considered to be an important indicator of poor prognosis. [27] [28] [29] Recent studies have shown that STAT3 inhibition suppresses cell growth or enhances apoptosis in multiple cancer cell lines. 30, 31 Conversely, constitutively activated STAT3 signaling has been found in tumor cells and has been demonstrated to promote cell cycle progression and prevent apoptosis by modulating cell cycle-and apoptosis-associated proteins such as cyclin D1 and Bcl-2. [27] [28] [29] In squamous cell carcinomas, increased STAT3 activation has been found to enhance cell proliferation and migration, while siRNA-mediated stat3 gene silencing efficiently inhibited STAT3 activation, increased tumor cell apoptosis, and dramatically decreased tumor growth in vitro and in vivo. 32, 33 While STAT3 is a potent therapeutic target involved in the progression of multiple cancers, the activation of STAT3 and the upstream molecular events in esophageal tumor cells have not been well characterized.
In the present study, we found that the expression of total GSK3β is higher, but phosphorylated GSK3β is lower, in cancerous tissues from ESCC patients. GSK3β inhibition suppresses the growth of ESCC cells in vitro and in vivo by modifying the activity of STAT3. The expression levels of GSK3β and STAT3 in cancerous tissues are associated with the differentiation, metastasis, and prognosis of ESCC.
These results suggest that GSK3β and the downstream molecule STAT3 could be diagnostic biomarkers and/or potential therapeutic targets in the treatment of ESCC.
| MATERIALS AND METHODS
The study was approved by the Institutional Review Board of Henan University of Science and Technology (HUST). Overall survival rates were determined over 48 months.
| Patients and human tissue samples

| Immunohistochemistry
Tissues were fixed in formalin and then embedded in paraffin. Serial sections of 4 μm thickness were prepared and deparaffinized by submersion in three separate concentrations of ethanol (100%, 95%, and 70%), followed by rinsing continuously in distilled water for 5 min. (Y705F). Then, a scratch wound was made using a pipette tip.
The medium was replaced, and the wounds were photographed at 0, 
| Statistical analysis
The Kaplan-Meier method was used to generate time-to-progression and survival curves. The statistical analysis was performed with SPSS, and statistical significance was set at 0.05. For analyses of categorical data (tumor stage, tumor grade, and residual tumor size), Fisher's exact test was used to calculate P values. Results were presented as mean ± standard error of the mean when applicable. Tumor volume, weight, and tumor cell viability were analyzed using analysis of variance (ANOVA) followed by Dunnett test for comparison of treatment versus control groups. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc, San Diego, CA).
Differences were considered significance at P < 0.05. expression was primarily immunolocalized in the cytoplasm and occasionally present in nuclei, which is consistent with previous reports in other cancerous tissues. [36] [37] [38] We next used qRT-PCR to examine the expression of GSK3β transcripts and observed a similar trend, as shown in Fig. 1B , with higher expression and transcript levels of GSK3β observed in ESCC cancerous tissues compared with adjacent control tissues (Fig. 1B) . The average fold increase in GSK3β mRNA in cancerous tissue was significantly higher than that in control tissues (Fig. 1D ). Since GSK3β is constitutively active in resting cells and can be inactivated by phosphorylation at an N-terminal serine residue (Serine 9), we next examined the level of phosphorylated GSK3β in esophageal tissue sections from ESCC patients. Due to the lack of an available high-quality phospho-GSK3β
antibody for IHC, we used Western blot analysis to examine phospho-GSK3β expression and surprisingly observed that the expression level of phospho-GSK3β (Ser9), unlike that of total GSK3β, was significantly decreased in the cancerous tissues compared with adjacent control tissues (Fig. 1C,E) . These results
show for the first time the expression profile of total and phospho-GSK3β and indicate that GSK3β activity is increased in the cancerous tissue of ESCC patients.
| GSK3β expression is associated with the progression and prognosis of esophageal cancer
Because high expression of the active form of GSK3β was more frequently detected in cancerous tissues, we next analyzed the Fig. 2A , Table 2 ).
Collectively, these results suggest that GSK3β expression is closely related to ESCC development and that higher GSK3β activity is an indicator of poorer differentiation, higher metastasis rates, and worse prognosis. (Fig. 3E) . We further determined the impact of GSK3β inhibition on the migration of these cancer cells using a wound healing assay. Inhibiting GSK3β with either a pharmacological inhibitor or a specific siRNA significantly reduced the migration of KYSE-30 ( Fig. 3F-I ) and KYSE-70 ( Fig. 3J-M Collectively, these data indicated that GSK3β inhibition leads to decreased STAT3 phosphorylation in ESCC cells. The Cancer Phosphorylation Profiling (PAC-155) antibody microarray identified a list of phosphorylated proteins whose phosphorylation states decreased in the presence of LiCl sodium (25 mM). The ratio of the phosphorylated proteins between LiCl-treated group and non-stimulated control group at indicated time point was shown. "−" and "+" represent "decrease" and "increase," respectively. 
| Cancer signaling phospho-antibody array shows that GSK3β inhibition suppresses STAT3 activity
| GSK3 inhibition-mediated suppression of cancer cell viability is dependent on STAT3 activation
As we demonstrated that GSK3β inhibition suppresses STAT3 phosphorylation, we next investigated if the suppressive effect of GSK3β inhibition on the viability and migration of ESCC cells is mediated by STAT3 modifications. To this end, we first confirmed the effect of GSK3β on STAT3 phosphorylation using a GSK3β-specific siRNA and a constitutively active mutant of GSK3β, GSK3β
(S9A). Specific GSK3β siRNA led to a substantial reduction of GSK3β expression (Fig. 6A ) and a considerable decrease of the STAT3 phosphorylation in KYSE-70 cells compared with the control cells (Fig. 6A,B) , while constitutively active GSK3β considerably increased STAT3 phosphorylation (Fig. 6C,D) , suggesting that GSK3β inhibition indeed reduces STAT3 phosphorylation in ESCC cells. We next used MTT and wound healing assays to examine the role of STAT3 in the ( Fig. 6E,F ) and the viability of ESCC cells and abrogated the antiproliferative effect of GSK3 inhibition on KYSE-70 cells (Fig. 6H) . By contrast, a STAT3 inhibitor, WP-1066, enhanced the suppressive effect of the GSK3 inhibitor on the viability of KYSE-70 cells (Fig. 6I) .
These results are consistent with previous studies indicating that STAT3 inhibition suppressed the growth of ESCC cells, while STAT3 activation had the opposite effect. [44] [45] [46] Similar effects were observed in the wound healing assay. Active STAT3 enhanced cell migration and offset the suppressive effect of LiCl on the migration of KYSE-70 cells (Fig. 6J,L) . By contrast, the STAT3 inhibitor (WP-1066) substantially enhanced the suppressive effect of LiCl (Fig. 6K,   M) . Collectively, these results demonstrated that the ability of GSK3 inhibition to suppress the viability of ESCC cells is dependent at least in part on the activity of STAT3. Notably, the direct association of GSK3β and STAT3 was not observed when we imunoprecipitated GSK3β and tested the expression of total STAT3 in the presence or absence of LiCl treatments (Fig. 6G) , which indicated other molecules may be involved in the regulatory effects of GSK3β on STAT3 activation in tumor cells. LiCl-treated mice compared with the control mice (Fig. 7D) , indicating the in vivo inhibitory effect of LiCl on STAT3 phosphorylation.
Importantly, compared with a single dose of either inhibitor, the 
FIGURE 6
GSK3β inhibition-mediated suppression of cancer cell viability and migration is dependent on STAT3 activation. KYSE-70 cells were transfected with a GSK3β-specific siRNA (A), a constitutively active mutant of GSK3β (S9A) (C), or a mutant plasmid STAT3 (Y705F) (E), or the relevant control including a scramble siRNA and empty control plasmids for 48 h, and whole-cell lysates were then collected and analyzed by immunoblot using antibodies against phospho-STAT3/total STAT3, HA tag, FLAG tag, and tubulin (A, C, and E). GSK3β has been shown to suppress the Wnt/β-catenin pathway by phosphorylating β-catenin, resulting in the ubiquitin/proteasomedependent degradation of β-catenin. 47 Since the accumulation of β-catenin has been demonstrated to promote the development of multiple cancers, 48, 49 GSK3β was thought to act as a tumor suppressor Moreover, GSK3β overexpression has been reported to affect the viability of cancer cells by enhancing the degradation of protumorigenesis factors such as Cdc25A and c-Myc. 24, 52 On the other hand, the pro-tumorigenesis role of GSK3β has also been observed in various tumor types including colon, liver, ovarian, and pancreatic cancer with underlying molecular mechanisms of controlling the expression of cyclin proteins or modifying the activity of telomerase. [53] [54] [55] Moreover, GSK3β inhibition has been shown to enhance lysosomal acidification and thus increase the degradation of the epidermal growth factor receptor, 56 indicating an alternative protumorigenesis mechanism of GSK3β. Here, we provided direct evidence of higher expression of the active GSK3β form in the cancerous tissues of ESCC patients than in normal tissues and elucidate a novel molecular mechanism by which GSK3β promotes the viability and migration of ESCC cells in vitro and in vivo that involves regulating STAT3 phosphorylation (Fig. 8) Higher levels of GSK3β activation increased the phosphorylation of STAT3 and by which promoted cancer cell survival and progression of ESCC (Green arrows). In contrast, inhibition of GSK3β by LiCl or SB216763 reduced phosphorylation of STAT3 and consequently suppressed the growth of cancer cell (Pink arrows). Direct association between GSK3β and STAT3 was not observed in this study. Other factors, that is, IL-6, might be involved in this process. GSK3β activation could enhance the production of IL-6, and through which facilitate the phosphorylation of STAT3 and promote the growth of ESCC cells cytokines (such as IL-6) and is involved in cytokine signaling. 34 Since STAT3 phosphorylation mediated by cytokines (such as IL-6) also plays a critical role in the progression of cancer, it is possible that GSK3β regulates STAT3 phosphorylation by modifying the amount and subsequent signaling of certain cytokines, for example, IL-17 and IL-6 (Fig.8) .
In summary, our current study identified 
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